Evaluation and management of dry mouth and its complications in rheumatology practice

References

• Scully C, DH F. Oral medicine – update for the dental practitioner: dry mouth and disorders of salivation. Br Dent J. 2005 Oct 8;199:423–427.
   PubMed Web of Science ®Google Scholar
• Lofgren CD, Wickstrom C, Sonesson M, et al. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012 Aug 8;12(1):29. doi: 10.1186/1472-6831-12-29
   PubMedGoogle Scholar
• Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc. 1987 Oct;115(4):581–584. doi: 10.1016/S0002-8177(87)54012-0
   PubMed Web of Science ®Google Scholar
• Chaudhury NM, Proctor GB, Karlsson NG, et al. reduced mucin-7 (Muc7) Sialylation and altered saliva rheology in Sjögren’s syndrome associated Oral dryness. Mol & Cell Proteomics. 2016 Mar;15(3):1048–1059. doi: 10.1074/mcp.M115.052993
   PubMed Web of Science ®Google Scholar
• Billings M, Dye BA, Iafolla T, et al. Significance and Implications of patient-reported xerostomia in Sjogren’s syndrome. Findings From The National Institutes Of Health Cohort. EBioMedicine. 2016 Oct;12:270–279.
   PubMed Web of Science ®Google Scholar
• Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987 Feb;66(1_suppl):Spec No:648–53. doi: 10.1177/00220345870660S107
   Google Scholar
• Dawes C, Pedersen AM, Villa A, et al. The functions of human saliva: a review sponsored by the world workshop on Oral medicine VI. Arch Oral Biol. 2015 Jun;60(6):863–874. doi: 10.1016/j.archoralbio.2015.03.004
   PubMed Web of Science ®Google Scholar
• Redman RS. On approaches to the functional restoration of salivary glands damaged by radiation therapy for head and neck cancer, with a review of related aspects of salivary gland morphology and development. Biotechnic Histochemist. 2008 Jun;83(3–4):103–130. doi: 10.1080/10520290802374683
   PubMed Web of Science ®Google Scholar
• Mercadante V, Jensen SB, Smith DK, et al. Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO guideline. J Clin Oncol. 2021 Sep 1;39(25):2825–2843. doi: 10.1200/JCO.21.01208
   PubMed Web of Science ®Google Scholar
• Proctor GB. The physiology of salivary secretion. Periodontol 2000. 2016 Feb;70(1):11–25. doi: 10.1111/prd.12116
   PubMed Web of Science ®Google Scholar
• Percival RS, Challacombe SJ, Marsh PD. Flow rates of resting whole and stimulated parotid saliva in relation to age and gender. J Dent Res. 1994 Aug;73(8):1416–1420. doi: 10.1177/00220345940730080401
   PubMed Web of Science ®Google Scholar
• Vissink A, Spijkervet FK, Van Nieuw Amerongen A. Aging and saliva: a review of the literature. Spec Care Dentist. 1996 May;16(3):95–103. doi: 10.1111/j.1754-4505.1996.tb00842.x
   PubMedGoogle Scholar
• Inoue H, Ono K, Masuda W, et al. Gender difference in unstimulated whole saliva flow rate and salivary gland sizes. Arch Oral Biol. 2006 Dec;51(12):1055–1060. doi: 10.1016/j.archoralbio.2006.06.010
   PubMed Web of Science ®Google Scholar
• Shern RJ, Fox PC, Li SH. Influence of age on the secretory rates of the human minor salivary glands and whole saliva. Arch Oral Biol. 1993 Sep;38(9):755–761. doi: 10.1016/0003-9969(93)90071-S
   PubMed Web of Science ®Google Scholar
• Affoo RH, Foley N, Garrick R, et al. Meta-analysis of salivary flow rates in Young and older adults. J Am Geriatr Soc. 2015 Oct;63(10):2142–2151. doi: 10.1111/jgs.13652
   PubMed Web of Science ®Google Scholar
• Kho HS. Understanding of xerostomia and strategies for the development of artificial saliva. Chin J Dent Res. 2014;17(2):75–83.
   PubMedGoogle Scholar
• Osailan S, Pramanik R, Shirodaria S, et al. Investigating the relationship between hyposalivation and mucosal wetness. Oral Dis. 2011 Jan;17(1):109–114. doi: 10.1111/j.1601-0825.2010.01715.x
   PubMed Web of Science ®Google Scholar
• Vinke J, Oude Elberink M, Stokman MA, et al. Lubricating properties of chewing stimulated whole saliva from patients suffering from xerostomia. Clin Oral Investig. 2021 Jul;25(7):4459–4469. doi: 10.1007/s00784-020-03758-8
   PubMed Web of Science ®Google Scholar
• Levine MJ. Salivary macromolecules. A structure/function synopsis. Ann N Y Acad Sci. 1993 Sep 20;694(1):11–16. doi: 10.1111/j.1749-6632.1993.tb18337.x
   PubMedGoogle Scholar
• Johansson AK, Johansson A, Unell L, et al. Self-reported dry mouth in Swedish population samples aged 50, 65 and 75 years. Gerodontology. 2012 Jun;29(2):e107–15. doi: 10.1111/j.1741-2358.2010.00420.x
   PubMed Web of Science ®Google Scholar
• Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Oral Epidemiol. 1996 Oct;24(5):312–316. doi: 10.1111/j.1600-0528.1996.tb00868.x
   PubMed Web of Science ®Google Scholar
• Hay EM, Thomas E, Pal B, et al. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis. 1998 Jan;57(1):20–24. doi: 10.1136/ard.57.1.20
   PubMed Web of Science ®Google Scholar
• Benn AM, Broadbent JM, Thomson WM. Occurrence and impact of xerostomia among dentate adult New Zealanders: findings from a national survey. Aust Dent J. 2015 Sep;60(3):362–367. doi: 10.1111/adj.12238
   PubMed Web of Science ®Google Scholar
• Ohara Y, Hirano H, Yoshida H, et al. Prevalence and factors associated with xerostomia and hyposalivation among community-dwelling older people in Japan. Gerodontology. 2016 Mar;33(1):20–27. doi: 10.1111/ger.12101
   PubMed Web of Science ®Google Scholar
• So JS, Chung SC, Kho HS, et al. Dry mouth among the elderly in Korea: a survey of prevalence, severity, and associated factors. Oral Surg, Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):475–483. doi: 10.1016/j.tripleo.2010.05.004
   PubMed Web of Science ®Google Scholar
• Nederfors T, Isaksson R, Mornstad H, et al. Prevalence of perceived symptoms of dry mouth in an adult Swedish population–relation to age, sex and pharmacotherapy. Oral Epidemiol. 1997 Jun;25(3):211–216. doi: 10.1111/j.1600-0528.1997.tb00928.x
   PubMed Web of Science ®Google Scholar
• Gilbert GH, Heft MW, Duncan RP. Mouth dryness as reported by older Floridians. Oral Epidemiol. 1993 Dec;21(6):390–397. doi: 10.1111/j.1600-0528.1993.tb01105.x
   PubMed Web of Science ®Google Scholar
• Morita I, Morioka H, Abe Y, et al. Discordance between hyposalivation and xerostomia among community-dwelling older adults in Japan. PLoS One. 2023;18(3):e0282740. doi: 10.1371/journal.pone.0282740
   PubMed Web of Science ®Google Scholar
• Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009 May 27;7(1):46. doi: 10.1186/1477-7525-7-46
   PubMedGoogle Scholar
• Enger TB, Palm O, Garen T, et al. Oral distress in primary Sjögren’s syndrome: implications for health-related quality of life. Eur J Oral Sci. 2011 Dec;119(6):474–480. doi: 10.1111/j.1600-0722.2011.00891.x
   PubMed Web of Science ®Google Scholar
• Lendrem D, Mitchell S, McMeekin P, et al. Health-related utility values of patients with primary Sjögren’s syndrome and its predictors. Ann Rheum Dis. 2014 Jul;73(7):1362–1368. doi: 10.1136/annrheumdis-2012-202863
   PubMed Web of Science ®Google Scholar
• Rusthen S, Young A, Herlofson BB, et al. Oral disorders, saliva secretion, and oral health-related quality of life in patients with primary Sjögren’s syndrome. Eur J Oral Sci. 2017 Aug;125(4):265–271. doi: 10.1111/eos.12358
   PubMed Web of Science ®Google Scholar
• Giuca MR, Miceli M, Carli E, et al. Impact of Sjögren’s syndrome on oral health and quality of life: an observational cross-sectional study. J Biol Regul Homeost Agents. 2020 May;34(3 Suppl. 1):129–137. DENTAL SUPPLEMENT.
   PubMedGoogle Scholar
• Iwasaki M, Borgnakke WS, Yoshihara A, et al. Hyposalivation and 10-year all-cause mortality in an elderly Japanese population. Gerodontology. 2018 Jun;35(2):87–94. doi: 10.1111/ger.12319
   PubMed Web of Science ®Google Scholar
• Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med. 2017 Dec;6(12):2918–2931. doi: 10.1002/cam4.1221
   PubMed Web of Science ®Google Scholar
• Schubert MM, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. J Dent Res. 1987 Feb;66(1_suppl):Spec No: 680–8. doi: 10.1177/00220345870660S113
   Google Scholar
• Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003 Jul;9(4):165–176. doi: 10.1034/j.1601-0825.2003.03967.x
   PubMed Web of Science ®Google Scholar
• Wolff A, Joshi RK, Ekstrom J, et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective Sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D. 2017 Mar;17:1–28. doi: 10.1007/s40268-016-0153-9
   PubMed Web of Science ®Google Scholar
• Villa A, Wolff A, Aframian D, et al. World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. Clin Oral Investig. 2015 Sep;19(7):1563–1580. doi: 10.1007/s00784-015-1488-2
   PubMed Web of Science ®Google Scholar
• Tan ECK, Lexomboon D, Sandborgh-Englund G, et al. Medications that cause dry mouth as an adverse effect in older people: a systematic review and metaanalysis. J Am Geriatr Soc. 2018 Jan;66(1):76–84. doi: 10.1111/jgs.15151
   PubMed Web of Science ®Google Scholar
• Fortuna G, Whitmire S, Sullivan K, et al. Impact of medications on salivary flow rate in patients with xerostomia: a retrospective study by the xeromeds consortium. Clin Oral Investig. 2023 Jan;27(1):235–248. doi: 10.1007/s00784-022-04717-1
   PubMed Web of Science ®Google Scholar
• Zavras AI, Rosenberg GE, Danielson JD, et al. Adverse drug and device reactions in the oral cavity: surveillance and reporting. J Am Dent Assoc. 2013 Sep;144(9):1014–1021. doi: 10.14219/jada.archive.2013.0228
   PubMed Web of Science ®Google Scholar
• Verhoeff MC, Koutris M, Vries R, et al. Salivation in Parkinson’s disease: a scoping review. Gerodontology. 2023 Mar;40:26–38.
   PubMedGoogle Scholar
• Barbe AG, Heinzler A, Derman S, et al. Hyposalivation and xerostomia among Parkinson’s disease patients and its impact on quality of life. Oral Dis. 2017 May;23(4):464–470. doi: 10.1111/odi.12622
   PubMed Web of Science ®Google Scholar
• Ho DS, Vaou OE, Hohler AD. Dry eye syndrome and sicca complex are commonly found in patients with postural orthostatic tachycardia syndrome. Clin Ophthalmol. 2020;14: 4015–4021. doi: 10.2147/OPTH.S279520
   PubMed Web of Science ®Google Scholar
• Palma JA, Gupta A, Sierra S, et al. Autoantibodies blocking M 3 muscarinic receptors cause Postganglionic cholinergic Dysautonomia. Ann Neurol. 2020 Dec;88(6):1237–1243. doi: 10.1002/ana.25882
   PubMed Web of Science ®Google Scholar
• Spadari F, Venesia P, Azzi L, et al. Low basal salivary flow and burning mouth syndrome: new evidence in this enigmatic pathology. J Oral Pathol Med. 2015 Mar;44(3):229–233. doi: 10.1111/jop.12240
   PubMed Web of Science ®Google Scholar
• Lee YC, Hong IK, Na SY, et al. Evaluation of salivary function in patients with burning mouth syndrome. Oral Dis. 2015 Apr;21(3):308–313. doi: 10.1111/odi.12270
   PubMed Web of Science ®Google Scholar
• Poon R, Su N, Ching V, et al. Reduction in unstimulated salivary flow rate in burning mouth syndrome. Br Dent J. 2014 Oct;217(7):E14. doi: 10.1038/sj.bdj.2014.884
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Baer AN, Shiboski SC, et al. Natural history and predictors of progression to Sjögren’s syndrome among participants of the Sjögren’s International Collaborative clinical Alliance registry. Arthritis Care & Research. 2018 Feb;70(2):284–294. doi: 10.1002/acr.23264
   Web of Science ®Google Scholar
• Fox RI, Maruyama T. Pathogenesis and treatment of Sjogren’s syndrome. Curr Opin Rheumatol. 1997 Sep;9(5):393–399. doi: 10.1097/00002281-199709000-00004
   PubMedGoogle Scholar
• Mona M, Mondello S, Hyon JY, et al. Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2021 Jul;39(4):795–803. doi: 10.55563/clinexprheumatol/gy6udz
   PubMed Web of Science ®Google Scholar
• Carpenter G. Dry mouth : a clinical guide on causes, effects and treatments. Berlin (Heidelberg): Springer Berlin Heidelberg; 2015. Imprint: Springer.
   Google Scholar
• Carlson ER, Ord RA. Salivary gland pathology : diagnosis and management. Hoboken (NJ): Wiley/Blackwell,; 2015.
   Google Scholar
• Bologna SB, Nico MMS, Florezi G, et al. Peculiar histopathological features in minor salivary gland in lupus erythematosus. Lupus. 2018 Sep;27(10):1706–1711. doi: 10.1177/0961203318790672
   PubMed Web of Science ®Google Scholar
• Skopouli F, Siouna-Fatourou H, Dimou GS, et al. Histologic lesion in labial salivary glands of patients with systemic lupus erythematosus. Oral Surg Oral Med Oral Pathol. 1991 Aug;72(2):208–212. doi: 10.1016/0030-4220(91)90165-9
   PubMedGoogle Scholar
• Osial TA Jr., Whiteside TL, Buckingham RB, et al. Clinical and serologic study of Sjogren's syndrome in patients with progressive systemic sclerosis. Arthritis Rheum. 1983 Apr;26(4):500–508. doi: 10.1002/art.1780260408
   PubMedGoogle Scholar
• Baer AN, Medrano L, McAdams-DeMarco M, et al. Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjögren’s syndrome: analysis of the Sjögren’s International Collaborative clinical Alliance cohort. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1554–1559. doi: 10.1002/acr.22859
   PubMed Web of Science ®Google Scholar
• Baron M, Hudson M, Tatibouet S, et al. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology (Oxford). 2014 Aug;53(8):1386–1394. doi: 10.1093/rheumatology/ket441
   PubMed Web of Science ®Google Scholar
• Li W, Chen Y, Sun ZP, et al. Clinicopathological characteristics of immunoglobulin G4-related sialadenitis. Arthritis Res Ther. 2015 Jul 21;17(1):186. doi: 10.1186/s13075-015-0698-y
   PubMedGoogle Scholar
• Moriyama M, Ohta M, Furukawa S, et al. The diagnostic utility of labial salivary gland biopsy in IgG4-related disease. Mod Rheumatol. 2016 Sep;26(5):725–729. doi: 10.3109/14397595.2016.1148225
   PubMed Web of Science ®Google Scholar
• Gogel HK, Searles RP, Volpicelli NA, et al. Primary amyloidosis presenting as Sjögren’s syndrome. Arch Intern Med. 1983 Dec;143(12):2325–2326. doi: 10.1001/archinte.1983.00350120123027
   PubMedGoogle Scholar
• Catalano MA, Vaughan JH. Secondary amyloidosis and sicca syndrome. Arthritis Rheum. 1980 Sep;23(9):1067. doi: 10.1002/art.1780230921
   PubMedGoogle Scholar
• Jardinet D, Westhovens R, Peeters J. Sicca syndrome as an initial symptom of amyloidosis. Clin Rheumatol. 1998;17(6):546–548. doi: 10.1007/BF01451299
   PubMed Web of Science ®Google Scholar
• Simon BG, Moutsopoulos HM. Primary amyloidosis resembling sicca syndrome. Arthritis Rheum. 1979 Aug;22(8):932–934. doi: 10.1002/art.1780220821
   PubMedGoogle Scholar
• Jamet MP, Gnemmi V, Hachulla E, et al. Distinctive patterns of transthyretin amyloid in salivary tissue: a clinicopathologic study of 92 patients with amyloid-containing minor salivary gland biopsies. Am J Surg Pathol. 2015 Aug;39(8):1035–1044. doi: 10.1097/PAS.0000000000000430
   PubMed Web of Science ®Google Scholar
• Fatihi E, Zahiri K, Hachim K, et al. Intérêt de la biopsie des glandes salivaires accessoires dans l’amylose. Rev Med Interne. 1999 Sep;20(9):759–761. doi: 10.1016/S0248-8663(00)88681-6
   PubMedGoogle Scholar
• Suzuki T, Kusumoto S, Yamashita T, et al. Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis. Ann Hematol. 2016 Jan;95(2):279–285. doi: 10.1007/s00277-015-2549-y
   PubMed Web of Science ®Google Scholar
• Mercan R, Bitik B, Tezcan ME, et al. Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic. ISRN Rheumatol. 2014;2014:354648. doi: 10.1155/2014/354648
   PubMedGoogle Scholar
• Ungprasert P, Crowson CS, Matteson EL. Clinical characteristics of parotid gland sarcoidosis: a population-based study. JAMA Otolaryngology–Head & Neck Surg. 2016 May 1;142(5):503–504. doi: 10.1001/jamaoto.2016.0061
   PubMed Web of Science ®Google Scholar
• James DG, Sharma OP. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2000 Mar;17(1):27–32.
   PubMed Web of Science ®Google Scholar
• Harvey J, Catoggio L, Gallagher PJ, et al. Salivary gland biopsy in sarcoidosis. Sarcoidosis. 1989 Mar;6(1):47–50.
   PubMedGoogle Scholar
• Nessan VJ, Jacoway JR, Lauttman RJ. Biopsy of minor salivary glands in the diagnosis of sarcoidosis. N Engl J Med. 1979 Oct 25;301(17):922–924. doi: 10.1056/NEJM197910253011705
   PubMed Web of Science ®Google Scholar
• Dempsey OJ, Paterson EW, Kerr KM, et al. Sarcoidosis. BMJ. 2009 Aug 28;339(aug28 1):b3206. doi: 10.1136/bmj.b3206
   PubMedGoogle Scholar
• Drosos AA, Voulgari PV, Psychos DN, et al. Sicca syndrome in patients with sarcoidosis. Rheumatol Int. 1999;18(5–6):177–180. doi: 10.1007/s002960050081
   PubMed Web of Science ®Google Scholar
• Hofauer B, Wiesner M, Zhu Z, et al. Persisting sicca complaints in sarcoidosis. Front Med. 2022;9:975122. doi: 10.3389/fmed.2022.975122
   Web of Science ®Google Scholar
• Huang N, Perez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021 May;27(5):892–903. doi: 10.1038/s41591-021-01296-8
   PubMed Web of Science ®Google Scholar
• Shen Y, Voigt A, Goranova L, et al. Evidence of a Sjögren's disease-like phenotype following COVID-19 in mice and human. JCI Insight. 2023 sep; 7: e166540. doi: 10.1172/jci.insight.166540
   PubMedGoogle Scholar
• Ramos-Casals M, Font J, Ingelmo M. Prevalencia y significado clínico de la infección crónica por el virus de la hepatitis C en las enfermedades autoinmunes sistémicas. Med Clin. 2001 May 19;116(18):701–709. doi: 10.1016/S0025-7753(01)71958-6
   PubMedGoogle Scholar
• Ferreiro MC, Prieto MH, Rodriguez SB, et al. Whole stimulated salivary flow in patients with chronic hepatitis C virus infection. J Oral Pathol Med. 2002 Feb;31(2):117–120. doi: 10.1046/j.0904-2512.2001.00185.x
   PubMed Web of Science ®Google Scholar
• Maldonado JO, Beach ME, Wang Y, et al. HCV infection alters salivary gland histology and saliva composition. J Dent Res. 2022 May;101(5):534–541. doi: 10.1177/00220345211049395
   PubMed Web of Science ®Google Scholar
• Meer S. Human immunodeficiency virus and salivary gland pathology: an update. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Jul;128(1):52–59. doi: 10.1016/j.oooo.2019.01.001
   PubMed Web of Science ®Google Scholar
• Rath IBD, Beltrame APCA, Carvalho AP, et al. HIV -associated salivary gland disease – clinical or imaging diagnosis? Int J Paediatr Dent. 2015 Jul;25(4):233–238. doi: 10.1111/ipd.12133
   PubMed Web of Science ®Google Scholar
• Patton LL, McKaig R, Strauss R, et al. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg, Oral Med Oral Pathol Oral Radiol Endod. 2000 Mar;89(3):299–304. doi: 10.1016/S1079-2104(00)70092-8
   PubMed Web of Science ®Google Scholar
• Navazesh M, Mulligan R, Karim R, et al. Effect of HAART on salivary gland function in the women’s interagency HIV study (WIHS). Oral Dis. 2009 Jan;15(1):52–60. doi: 10.1111/j.1601-0825.2008.01456.x
   PubMed Web of Science ®Google Scholar
• Nittayananta W, Chanowanna N, Pruphetkaew N, et al. Relationship between xerostomia and salivary flow rates in HIV-infected individuals. J Investig Clin Dent. 2013 Aug;4(3):164–171. doi: 10.1111/jicd.12052
   PubMedGoogle Scholar
• Lopez-Jornet P, Camacho-Alonso F, Bermejo-Fenoll A. A simple test for salivary gland hypofunction using Oral Schirmer’s test. J Oral Pathol Med. 2006 Apr;35(4):244–248. doi: 10.1111/j.1600-0714.2006.00411.x
   PubMed Web of Science ®Google Scholar
• Kumar JV, Baghirath PV, Naishadham PP, et al. Relationship of long-term highly active antiretroviral therapy on salivary flow rate and CD4 Count among HIV-infected patients. J Oral Maxillofac Pathol. 2015 Jan;19(1):58–63. doi: 10.4103/0973-029X.157203
   PubMedGoogle Scholar
• Caskey MF, Morgan DJ, Porto AF, et al. Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses. 2007 Mar;23(3):365–371. doi: 10.1089/aid.2006.0140
   PubMed Web of Science ®Google Scholar
• Saleem MKM, Lal A, Ahmed N, et al. Oral health related quality of life and the prevalence of ageusia and xerostomia in active and recovered COVID-19 patients. PeerJ. 2023;11:e14860. doi: 10.7717/peerj.14860
   PubMed Web of Science ®Google Scholar
• Binmadi NO, Aljohani S, Alsharif MT, et al. Oral manifestations of COVID-19: a cross-sectional study of their prevalence and Association with disease severity. J Clin Med. 2022 Jul 30;11(15):4461. doi: 10.3390/jcm11154461
   PubMed Web of Science ®Google Scholar
• Ittichaicharoen J, Chattipakorn N, Chattipakorn SC. Is salivary gland function altered in noninsulin-dependent diabetes mellitus and obesity-insulin resistance? Arch Oral Biol. 2016 Apr;64:61–71. doi: 10.1016/j.archoralbio.2016.01.002
   PubMed Web of Science ®Google Scholar
• Bossola M. Xerostomia in patients on chronic hemodialysis: an update. Semin Dial. 2019 Sep;32(5):467–474. doi: 10.1111/sdi.12821
   PubMed Web of Science ®Google Scholar
• Hoseini A, Mirzapour A, Bijani A, et al. Salivary flow rate and xerostomia in patients with type I and II diabetes mellitus. Electron Physician. 2017 Sep;9(9):5244–5249. doi: 10.19082/5244
   PubMedGoogle Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005 May 12;352(19):1992–2001. doi: 10.1056/NEJMra043184
   PubMed Web of Science ®Google Scholar
• Nordgarden H, Johannessen S, Storhaug K, et al. Salivary gland involvement in hypohidrotic ectodermal dysplasia. Oral Dis. 1998 Jun;4(2):152–154. doi: 10.1111/j.1601-0825.1998.tb00270.x
   PubMedGoogle Scholar
• Kozycki CT, Kodati S, Huryn L, et al. Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann Rheum Dis. 2022 Oct;81(10):1453–1464. doi: 10.1136/annrheumdis-2022-222629
   PubMed Web of Science ®Google Scholar
• Ferre EMN, Schmitt MM, Lionakis MS. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Front Pediatr. 2021;9:723532. doi: 10.3389/fped.2021.723532
   PubMed Web of Science ®Google Scholar
• Cooper JS, Fu K, Marks J, et al. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1141–1164. doi: 10.1016/0360-3016(94)00421-G
   PubMed Web of Science ®Google Scholar
• Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997 May;19(3):169–175. doi: 10.1002/(SICI)1097-0347(199705)19:3<169:AID-HED1>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):847–856. doi: 10.1016/0360-3016(94)90104-X
   PubMed Web of Science ®Google Scholar
• Dreyer JO, Sakuma Y, Seifert G. Radiation-induced sialadenitis. Stage classification and immunohistology. Pathologe. 1989 May;10(3):165–170.
   PubMedGoogle Scholar
• Albrecht HH, Creutzig H. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author’s transl). Fortschr Röntgenstr. 1976 Dec;125(12):546–551. doi: 10.1055/s-0029-1230516
   Google Scholar
• Newkirk KA, Ringel MD, Wartofsky L, et al. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J. 2000 Jun;79(6):460–468. doi: 10.1177/014556130007900612
   PubMedGoogle Scholar
• Kratochwil C, Afshar-Oromieh A, Kopka K, et al. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of Chelator Containing prostate-specific membrane antigen Ligands into Diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016 Sep;46(5):405–418. doi: 10.1053/j.semnuclmed.2016.04.004
   PubMed Web of Science ®Google Scholar
• Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant. 2010 Oct;16(10):1362–1369. doi: 10.1016/j.bbmt.2010.03.023
   PubMed Web of Science ®Google Scholar
• Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncology. 2019 Sep;24(9):1259–1269. doi: 10.1634/theoncologist.2018-0823
   Google Scholar
• Warner BM, Baer AN. Sicca syndromes. In: Suarez-Almazor ME, Calabrese LH, editors . Rheumatic diseases and syndromes induced by cancer immunotherapy. Cham, Switzerland: Springer Nature Switzerland; 2021. p. 109–142.
   Google Scholar
• Gulati A, Kidane J, Chang JL. Patient reported outcome measures for salivary function: a systematic review. Laryngoscope. 2023 Jan 6;133(8):1796–1805. doi: 10.1002/lary.30550
   PubMed Web of Science ®Google Scholar
• Thomson WM, Chalmers JM, Spencer AJ, et al. The xerostomia inventory: a multi-item approach to measuring dry mouth. Community Dent Health. 1999 Mar;16(1):12–17.
   PubMed Web of Science ®Google Scholar
• Osailan SM, Pramanik R, Shirlaw P, et al. Clinical assessment of oral dryness: development of a scoring system related to salivary flow and mucosal wetness. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Nov;114(5):597–603. doi: 10.1016/j.oooo.2012.05.009
   PubMed Web of Science ®Google Scholar
• Das P, Challacombe SJ. Dry mouth and clinical Oral dryness scoring systems. Prim Dent J. 2016 Feb 1;5(1):77–79. doi: 10.1177/205016841600500110
   PubMedGoogle Scholar
• Challacombe scale. Available from: http://www.challacombescale.co.uk/
   Google Scholar
• Chengappa RK, Narayanan VS, Khan AM, et al. Utility of two methodologies in the clinical assessment of oral dryness in postmenopausal women. J Midlife Health. 2016 Jul;7(3):114–118. doi: 10.4103/0976-7800.191014
   PubMedGoogle Scholar
• Hernandez YL, Daniels TE. Oral candidiasis in Sjögren’s syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol. 1989 Sep;68(3):324–329. doi: 10.1016/0030-4220(89)90218-1
   PubMedGoogle Scholar
• Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020 Jan;79(1):3–18. doi: 10.1136/annrheumdis-2019-216114
   PubMed Web of Science ®Google Scholar
• Speight PM, Kaul A, Melsom RD. Measurement of whole unstimulated salivary flow in the diagnosis of Sjogren’s syndrome. Ann Rheum Dis. 1992 Apr;51(4):499–502. doi: 10.1136/ard.51.4.499
   PubMed Web of Science ®Google Scholar
• Navazesh M, Kumar SK. University of Southern California School of D. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc. 2008 May;139(Suppl):35S–40S. doi: 10.14219/jada.archive.2008.0353
   PubMedGoogle Scholar
• Daniels TE. Do we need new diagnostic criteria for Sjögren’s syndrome? Presse Med. 2012 Sep;41(9):e441–9. doi: 10.1016/j.lpm.2012.05.023
   PubMedGoogle Scholar
• Liu Y, Li J, Tan YR, et al. Accuracy of diagnosis of salivary gland tumors with the use of ultrasonography, computed tomography, and magnetic resonance imaging: a meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Feb;119(2):238–45 e2. doi: 10.1016/j.oooo.2014.10.020
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhang Z, Fu K, et al. Diagnostic accuracy of parotid CT for identifying Sjögren’s syndrome. Eur J Radiol. 2012 Oct;81(10):2702–2709. doi: 10.1016/j.ejrad.2011.12.034
   PubMed Web of Science ®Google Scholar
• Seven B, Yoruk O, Varoglu E, et al. Evaluation by (99m)Tc-pertechnetate scintigraphy of the effect of levocetirizine on salivary glands function, in allergic rhinitis patients. Hell J Nucl Med. 2009 May;12(2):119–122.
   PubMed Web of Science ®Google Scholar
• Baer AN, McAdams DeMarco M, Shiboski SC, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis. 2015 Aug;74(8):1557–1561. doi: 10.1136/annrheumdis-2014-206683
   PubMed Web of Science ®Google Scholar
• Vivino FB, George M, Johr C, et al. Utility of testing for murine tissue specific autoantibodies for the diagnosis of Sjogren’s syndrome. Clin Exp Rheumatol. 2018;36:S256–S.
   PubMed Web of Science ®Google Scholar
• Daniels TE, Cox D, Shiboski CH, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren’s syndrome among 1,726 registry participants. Arthritis Rheum. 2011 Jul;63(7):2021–2030. doi: 10.1002/art.30381
   PubMed Web of Science ®Google Scholar
• Valdez RMA, Melo TS, Santos-Silva AR, et al. Adverse post-operative events of salivary gland biopsies: a systematic review and meta-analysis. J Oral Pathol Med. 2022 Feb;51(2):152–159. doi: 10.1111/jop.13229
   PubMed Web of Science ®Google Scholar
• Fisher BA, Jonsson R, Daniels T, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Ann Rheum Dis. 2017 Jul;76(7):1161–1168. doi: 10.1136/annrheumdis-2016-210448
   PubMed Web of Science ®Google Scholar
• Spijkervet FK, Haacke E, Kroese FG, et al. Parotid gland biopsy, the alternative Way to diagnose Sjögren syndrome. Rheum Dis Clin North Am. 2016 Aug;42(3):485–499. doi: 10.1016/j.rdc.2016.03.007
   PubMed Web of Science ®Google Scholar
• Baer AN, Grader-Beck T, Antiochos B, et al. Ultrasound-guided biopsy of suspected salivary gland lymphoma in Sjögren’s syndrome. Arthritis Care Res (Hoboken). 2021 Jun;73(6):849–855. doi: 10.1002/acr.24203
   PubMed Web of Science ®Google Scholar
• Deroo L, Genbrugge E, Dochy F, et al. Ultrasound-guided core needle biopsy and incisional biopsy of the parotid gland are comparable in diagnosis of primary Sjögren’s syndrome. Rheumatology (Oxford). 2023 Aug 1;62(8):2765–2772. doi: 10.1093/rheumatology/keac714
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three International patient cohorts. Arthritis & rheumat. 2016 2017 Jan;69(1):35–45. doi: 10.1002/art.39859
   PubMed Web of Science ®Google Scholar
• Xerostomia (dry mouth). Available from: https://www.ada.org/resources/research/science-and-research-institute/oral-health-topics/xerostomia
   Google Scholar
• Treating dry mouth available from: chrome extension://efaidnbmnnnibpcajpcglclefindmkaj/https://sjogrens.org/sites/default/files/inline-files/Sjogrens-DryMouth.pdf
   Google Scholar
• Dry mouth. Available from: https://www.nidcr.nih.gov/health-info/dry-mouth
   Google Scholar
• Furness S, Worthington HV, Bryan G, et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011 Dec 7:CD008934. doi: 10.1002/14651858.CD008934.pub2.
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Hosford DN, Sodini MA, et al. Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jul;116(1):e37–51. doi: 10.1016/j.oooo.2013.02.017
   PubMed Web of Science ®Google Scholar
• Napenas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology. 2009 Jul;97(2):76–83. doi: 10.1007/s10266-008-0099-7
   PubMed Web of Science ®Google Scholar
• Liu G, Qiu X, Tan X, et al. Efficacy of a 1% malic acid spray for xerostomia treatment: a systematic review and meta-analysis. Oral Dis. 2023 Apr;29(3):862–872. doi: 10.1111/odi.14116
   PubMed Web of Science ®Google Scholar
• Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome. Arch Intern Med. 2002 Jun 10;162(11):1293–1300. doi: 10.1001/archinte.162.11.1293
   PubMedGoogle Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome A randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med. 1999 Jan 25;159(2):174–181. doi: 10.1001/archinte.159.2.174
   PubMedGoogle Scholar
• Garlapati K, Kammari A, Badam RK, et al. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren’s syndrome. Immunopharmacol Immunotoxicol. 2019 Apr;41(2):312–318. doi: 10.1080/08923973.2019.1593448
   PubMed Web of Science ®Google Scholar
• Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2014 Jul;32(4):575–577.
   PubMed Web of Science ®Google Scholar
• Farag AM, Holliday C, Cimmino J, et al. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation. Oral Dis. 2019 Nov;25(8):1937–1944. doi: 10.1111/odi.13192
   PubMed Web of Science ®Google Scholar
• Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002 Mar;46(3):748–754. doi: 10.1002/art.510
   PubMed Web of Science ®Google Scholar
• Plemons JM, Al-Hashimi I, Marek CL, et al. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American dental Association Council on Scientific Affairs. J Am Dent Assoc. 2014 Aug;145(8):867–873. doi: 10.14219/jada.2014.44
   PubMed Web of Science ®Google Scholar
• Kamal Y, Kandil M, Eissa M, et al. Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren’s syndrome: a double-blinded, placebo-controlled, randomized trial. Rheumatol Int. 2020 Jun;40(6):873–879. doi: 10.1007/s00296-020-04558-9
   PubMed Web of Science ®Google Scholar
• Hagai A, Mohana A, Shalabi A, et al. Sialendoscopy enhances saliva production of parotid glands in primary Sjögren syndrome patients. Quintessence Int. 2023 Mar 17;54(3):234–240. doi: 10.3290/j.qi.b3609681
   PubMed Web of Science ®Google Scholar
• Aframian DJ, Baaton S, Mazor S, et al. Improvement of dry mouth following intraductal irrigation of salivary glands. Oral Dis. 2019 Oct;25(7):1735–1743. doi: 10.1111/odi.13152
   PubMed Web of Science ®Google Scholar
• Garcia MK, Chiang JS, Cohen L, et al. Acupuncture for radiation-induced xerostomia in patients with cancer: a pilot study. Head Neck. 2009 Oct;31(10):1360–1368. doi: 10.1002/hed.21110
   PubMed Web of Science ®Google Scholar
• Strietzel FP, Lafaurie GI, Mendoza GR, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 2011 Jan;63(1):180–190. doi: 10.1002/art.27766
   PubMedGoogle Scholar
• Luminet D. From metapsychology to object relations. Essay on psychosomatic clinical medicine. Evol Psychiatr (Paris). 1967 Jul;32(3):657–701.
   PubMedGoogle Scholar
• Fedele S, Al-Hamad A, Mercadante V, et al. Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren’s syndrome: a randomised sham-controlled feasibility study (LEONIDAS -1). J Oral Pathol Med. 2023 Aug;52(7):619–627. doi: 10.1111/jop.13452
   PubMed Web of Science ®Google Scholar
• Zero DT, Brennan MT, Daniels TE, et al. Clinical practice guidelines for oral management of Sjögren disease. J Am Dent Assoc. 2016 Apr;147(4):295–305. doi: 10.1016/j.adaj.2015.11.008
   PubMed Web of Science ®Google Scholar
• Xin W, Leung KC, Lo EC, et al. A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sjögren’s syndrome patients. BMC Oral Health. 2016 Sep 23;16(1):102. doi: 10.1186/s12903-016-0296-7
   PubMedGoogle Scholar
• Ericson D, Carlsson P, Gabre P, et al. Effect of a single application of silver diamine fluoride on root caries after 12 months in institutionalised older adults—A randomised clinical trial. Gerodontology. 2022 Nov 20;40(3):390–397. doi: 10.1111/ger.12668
   PubMedGoogle Scholar
• Sommerfeldt W, Gellert P, Muller A, et al. Older patients’ perception of treating root caries with silver diamine fluoride - a qualitative study based on the Theoretical Domains Framework. J Dent. 2023 Mar;130:104408.
   PubMed Web of Science ®Google Scholar
• Grandjean ML, Maccarone NR, McKenna G, et al. Silver diamine fluoride (SDF) in the management of root caries in elders: a systematic review and meta-analysis. Swiss Dent J. 2021 May 10;131(5):417–424.
   PubMedGoogle Scholar
• Young DA, Frostad-Thomas A, Gold J, et al. Secondary Sjögren syndrome. J Am Dent Assoc. 2018 Aug;149(8):731–741. doi: 10.1016/j.adaj.2018.03.021
   PubMed Web of Science ®Google Scholar
• Maarse F, Fennis WMM, Twisk JWR, et al. Dental implants in dentate primary and secondary Sjögren’s syndrome patients: a multicenter prospective cohort study. Clin Oral Implants Res. 2022 Nov;33(11):1157–1170. doi: 10.1111/clr.13998
   PubMed Web of Science ®Google Scholar
• Chowdhury F, Tappuni A, Bombardieri M. Biological therapy in primary Sjogren’s syndrome: effect on salivary gland function and inflammation. Front Med. 2021;8:707104. doi: 10.3389/fmed.2021.707104
   Web of Science ®Google Scholar
• Gueiros LA, France K, Posey R, et al. World Workshop on Oral medicine VII: immunobiologics for salivary gland disease in Sjogren’s syndrome: a systematic review. Oral Dis. 2019 Jun;25(Suppl 1):102–110. doi: 10.1111/odi.13062
   PubMedGoogle Scholar
• Choudhary R, Reddy SS, Nagaraju R, et al. Effectiveness of pharmacological interventions for Sjogren syndrome - a systematic review. J Clin Exp Dent. 2023 Jan;15:e51–e63.
   PubMedGoogle Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005 Sep;52(9):2740–2750. doi: 10.1002/art.21260
   PubMedGoogle Scholar
• Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and Oral dryness in primary Sjögren’s syndrome. Arthritis & Rheumat. 2017 Jul;69(7):1440–1450. doi: 10.1002/art.40093
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab. Ann Intern Med. 2014 Feb 18;160(4):233–242. doi: 10.7326/M13-1085
   PubMed Web of Science ®Google Scholar
• Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013 Oct 30;15(5):R172. doi: 10.1186/ar4359
   PubMed Web of Science ®Google Scholar
• Fisher BA, Szanto A, Ng WF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2020 Mar;2(3):E142–E52. doi: 10.1016/S2665-9913(19)30135-3
   Google Scholar
• He J, Chen J, Miao M, et al. Efficacy and safety of low-dose interleukin 2 for primary Sjögren syndrome. JAMA Netw Open. 2022 Nov 1;5(11):e2241451. doi: 10.1001/jamanetworkopen.2022.41451
   PubMed Web of Science ®Google Scholar
• Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021 Mar;80(3):329–338. doi: 10.1136/annrheumdis-2020-218467
   PubMed Web of Science ®Google Scholar
• van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2020 Mar;2(3):E153–E63. doi: 10.1016/S2665-9913(19)30160-2
   PubMedGoogle Scholar
• Cummins MJ, Papas A, Kammer GM, et al. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003 Aug 15;49(4):585–593. doi: 10.1002/art.11199
   PubMedGoogle Scholar
• Bowman SJ, Fox R, Dorner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161–171. doi: 10.1016/S0140-6736(21)02251-0
   PubMed Web of Science ®Google Scholar
• Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2021 Mar;80(3):339–348. doi: 10.1136/annrheumdis-2020-218599
   PubMed Web of Science ®Google Scholar
• Al Hamad A, Lodi G, Porter S, et al. Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: a systematic review and meta-analysis. Oral Dis. 2019 May;25(4):1027–1047. doi: 10.1111/odi.12952
   PubMed Web of Science ®Google Scholar
• Doolan G, Faizal NM, Foley C, et al. Treatment strategies for Sjögren’s syndrome with childhood onset: a systematic review of the literature. Rheumatology (Oxford). 2022 Mar 2;61(3):892–912. doi: 10.1093/rheumatology/keab579
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open. 2019;5(2):e001064. doi: 10.1136/rmdopen-2019-001064
   PubMed Web of Science ®Google Scholar
• Fallon BS, Chase TJ, Cooke EM, et al. The use of BokaFlo™ instrument to measure salivary flow. BMC Oral Health. 2021 Apr 12;21(1):191. doi: 10.1186/s12903-021-01477-4
   PubMed Web of Science ®Google Scholar
• Wang B, Chen S, Zheng Q, et al. Early diagnosis and treatment for Sjogren’s syndrome: current challenges, redefined disease stages and future prospects. J Autoimmun. 2021 Feb;117:102590.
   PubMed Web of Science ®Google Scholar
• Melguizo-Rodriguez L, Costela-Ruiz VJ, Manzano-Moreno FJ, et al. Salivary biomarkers and their application in the diagnosis and monitoring of the most common Oral pathologies. Int J Mol Sci. 2020 Jul 21;21(14):5173. doi: 10.3390/ijms21145173
   PubMed Web of Science ®Google Scholar
• Jimenez-Royo P, Bombardieri M, Ciurtin C, et al. Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren’s syndrome. Rheumatology (Oxford). 2021 May 14;60(5):2396–2408. doi: 10.1093/rheumatology/keaa624
   PubMed Web of Science ®Google Scholar
• Stefancu A, Badarinza M, Moisoiu V, et al. SERS-based liquid biopsy of saliva and serum from patients with Sjögren’s syndrome. Anal Bioanal Chem. 2019 Sep;411(22):5877–5883. doi: 10.1007/s00216-019-01969-x
   PubMed Web of Science ®Google Scholar
• Gomez Hernandez MP, Starman EE, Davis AB, et al. A distinguishing profile of chemokines, cytokines and biomarkers in the saliva of children with Sjögren’s syndrome. Rheumatology (Oxford). 2021 Oct 2;60(10):4765–4777. doi: 10.1093/rheumatology/keab098
   PubMed Web of Science ®Google Scholar
• Hernandez-Molina G, Michel-Peregrina M, Hernandez-Ramirez DF, et al. Chemokine saliva levels in patients with primary Sjogren’s syndrome, associated Sjogren’s syndrome, pre-clinical Sjogren’s syndrome and systemic autoimmune diseases. Rheumatology (Oxford). 2011 Jul;50(7):1288–1292. doi: 10.1093/rheumatology/ker019
   PubMed Web of Science ®Google Scholar
• Aqrawi LA, Galtung HK, Guerreiro EM, et al. Proteomic and histopathological characterisation of sicca subjects and primary Sjögren’s syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers. Arthritis Res Ther. 2019 Jul 31;21(1):181. doi: 10.1186/s13075-019-1961-4
   PubMedGoogle Scholar
• Lee J, Lee J, Baek S, et al. Soluble siglec-5 is a novel salivary biomarker for primary Sjogren’s syndrome. J Autoimmun. 2019 Jun;100:114–119.
   PubMed Web of Science ®Google Scholar
• Mohan V, Bruin NM, Steenbakkers R, et al. Dose response modelling of secretory cell loss in salivary glands using PSMA PET. Radiother Oncol. 2022 Dec;177:164–171.
   PubMed Web of Science ®Google Scholar
• Li JF, Qin LP, Wu QY, et al. The value of 68 Ga-PSMA-11 positron emission tomography/computerized tomography in evaluating the lacrimal and salivary glands function. Clin Rheumatol. 2022 May;41(5):1543–1550. doi: 10.1007/s10067-021-06038-2
   PubMed Web of Science ®Google Scholar
• Hahnel S, Behr M, Handel G, et al. Saliva substitutes for the treatment of radiation-induced xerostomia—a review. Support Care Cancer. 2009 Nov;17(11):1331–1343. doi: 10.1007/s00520-009-0671-x
   PubMed Web of Science ®Google Scholar
• Vinke J, Kaper HJ, Vissink A, et al. Dry mouth: saliva substitutes which adsorb and modify existing salivary condition films improve oral lubrication. Clin Oral Investig. 2020 Nov;24(11):4019–4030. doi: 10.1007/s00784-020-03272-x
   PubMed Web of Science ®Google Scholar
• Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19403–19407. doi: 10.1073/pnas.1210662109
   PubMed Web of Science ®Google Scholar
• Kojima T, Kanemaru S, Hirano S, et al. Regeneration of radiation damaged salivary glands with adipose-derived stromal cells. Laryngoscope. 2011 Sep;121(9):1864–1869. doi: 10.1002/lary.22080
   PubMed Web of Science ®Google Scholar
• Khalili S, Faustman DL, Liu Y, et al. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period. Cytotherapy. 2014 Mar;16(3):412–423. doi: 10.1016/j.jcyt.2013.10.006
   PubMed Web of Science ®Google Scholar
• Lim JY, Yi T, Choi JS, et al. Intraglandular transplantation of bone marrow-derived clonal mesenchymal stem cells for amelioration of post-irradiation salivary gland damage. Oral Oncol. 2013 Feb;49(2):136–143. doi: 10.1016/j.oraloncology.2012.08.010
   PubMed Web of Science ®Google Scholar
• Blitzer GC, Rogus-Pulia NM, Mattison RJ, et al. Marrow-derived autologous stromal cells for the restoration of salivary hypofunction (MARSH): study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: marrow-derived autologous stromal cells for the restoration of salivary hypofunction. Cytotherapy. 2022 May;24(5):534–543. doi: 10.1016/j.jcyt.2021.11.003
   PubMed Web of Science ®Google Scholar
• Piraino LR, Benoit DSW, DeLouise LA. Salivary gland tissue engineering approaches: state of the art and future directions. Cells. 2021 Jul 8;10(7):1723. doi: 10.3390/cells10071723
   PubMed Web of Science ®Google Scholar
• Burghartz M, Lennartz S, Schweinlin M, et al. Development of human salivary gland-like tissue in vitro. Tissue Eng Part A. 2018 Feb;24(3–4):301–309. doi: 10.1089/ten.tea.2016.0466
   PubMed Web of Science ®Google Scholar
• Iyer J, Pillai S, Munguia-Lopez JG, et al. Salivary gland bioengineering - yesterday, today, tomorrow! Histol Histopathol. 2023 Jun;38(6):607–621.
   PubMed Web of Science ®Google Scholar
• Chansaenroj A, Yodmuang S, Ferreira JN. Trends in salivary gland tissue engineering: from stem cells to secretome and Organoid Bioprinting. Tissue Eng Part B Rev. 2021 Apr;27(2):155–165. doi: 10.1089/ten.teb.2020.0149
   PubMed Web of Science ®Google Scholar
• Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren syndrome. Nat Rev Rheumatol. 2021 Aug;17(8):475–486. doi: 10.1038/s41584-021-00634-x
   PubMed Web of Science ®Google Scholar
• Accelerating medicines partnership. Available from: https://www.niams.nih.gov/grants-funding/niams-supported-research-programs/accelerating-medicines-partnership-amp
   Google Scholar